Founded in 2002, Alphalyse is a provider of advanced protein analysis, specializing in identifying unwanted impurities (host cell proteins, or "HCPs") in biologic drugs using mass spectrometry. These analyses are crucial for biotech and pharmaceutical companies to develop and ensure the safety of their biological drugs.

Alphalyse supports customers at every development stage, from discovery to commercial release, with quantitative, reproducible HCP data that de-risks regulatory submissions and shortens development timelines.

Fidelio partnered with Alphalyse in 2025 with the goal of establishing Alphalyse as the global reference in biologic HCP impurity analysis.